TB006 for Alzheimer’s and Dementia: A New Approach Through Galectin-3 Targeting

At Aevita Medical, we focus on bringing patients access to promising, forward-thinking therapies, especially in areas where conventional options fall short. One of the most exciting emerging treatments in neurodegenerative care is TB006, a novel monoclonal antibody currently being studied for Alzheimer’s disease and related dementias.

For families navigating cognitive decline, the reality is often frustrating. Most available medications aim to slow progression, but do not address the underlying disease process in a meaningful way. TB006 represents a different approach.

What Is TB006?

TB006 is a humanized monoclonal antibody designed to target Galectin-3 (Gal-3), a protein increasingly recognized as a key driver in neurodegeneration.

Galectin-3 plays a central role in:

• Neuroinflammation
• Toxic protein aggregation (including amyloid-beta and tau)
• Microglial activation and neuronal damage

In Alzheimer’s disease, these processes contribute to the buildup of plaques, ongoing inflammation, and progressive cognitive decline.

By blocking Galectin-3, TB006 is designed to:

• Reduce formation of toxic protein clusters
• Decrease inflammation in the brain
• Support improved neuronal communication

This “upstream” targeting approach is what makes TB006 fundamentally different from many currently available therapies.

Why Target Galectin-3?

Alzheimer’s disease is not caused by a single pathway. It is a complex condition involving inflammation, protein misfolding, vascular changes, and neuronal degeneration.

Galectin-3 appears to sit at the intersection of several of these processes:

• It acts as a binding agent that promotes harmful protein aggregation
• It drives inflammatory signaling in the brain
• It contributes to microglial overactivation and neuronal injury

Because of this, inhibiting Galectin-3 may offer a multi-targeted approach, rather than focusing on a single mechanism like amyloid clearance alone.

What Do the Clinical Results Show So Far?

TB006 has completed early-stage clinical trials, including a Phase 1b/2a study, with encouraging findings.

Key highlights:

• Improvement in cognitive measures such as MMSE after just one month of treatment
• Positive trends in Clinical Dementia Rating (CDR-SB) scores compared to placebo
• Evidence suggesting slowing or possible reversal of decline in some patients

In the Open Label Extension (OLE) study:

• Nearly half of patients treated for 3 months or longer showed cognitive improvement or signs of disease reversal
• Average treatment duration was around 8 months
• No serious treatment-related adverse events were reported

While these are early results, they represent a meaningful shift from the typical expectation of continued decline.

Safety and Tolerability

So far, TB006 has demonstrated a favorable safety profile.

Reported side effects have been:

• Generally mild
• Short-lived
• Most commonly related to infusion reactions

Other reported symptoms include:

• Headache
• Upset stomach
• Back pain

No severe adverse events directly linked to the medication have been reported in early trials.

How Is TB006 Administered?

TB006 is given as an intravenous (IV) infusion, typically:

• Once monthly
• Each infusion lasting about 1 hour
• Standard dose around 4000 mg per treatment

Treatment duration can vary depending on response and clinical goals.

What Is the Expanded Access Program (EAP)?

Because TB006 is not yet FDA-approved, it is currently available through an Expanded Access Program (EAP), sometimes called compassionate use.

This pathway allows patients to receive investigational therapies when:

• They have a serious condition such as Alzheimer’s disease
• They are not eligible for clinical trials
• They have exhausted standard treatment options

Typical eligibility includes:

• Age over 55
• Diagnosis of Alzheimer’s disease or related dementia
• Evidence of cognitive impairment
• Inability to enroll in a clinical trial

Who Might Be a Good Candidate?

At Aevita Medical, we evaluate each patient individually, but TB006 may be worth considering for:

• Patients with mild to moderate Alzheimer’s disease
• Individuals experiencing progressive cognitive decline despite standard therapies
• Families seeking access to emerging, mechanism-based treatments
• Patients interested in a more proactive or integrative care model

Our Approach at Aevita Medical

We take a personalized, concierge-style approach to neurodegenerative care. That means:

• Careful evaluation of candidacy for therapies like TB006
• Integration with functional and longevity-based strategies
• Ongoing monitoring of cognition, function, and quality of life
• Close collaboration with caregivers and families

Our goal is not just to slow decline, but to explore every reasonable path toward stabilization or improvement.

Final Thoughts

TB006 represents one of the more promising emerging therapies in Alzheimer’s care, particularly because it targets a broader disease pathway through Galectin-3.

While more research is still needed, early clinical data suggests:

• Potential cognitive improvement
• Favorable safety profile
• A new direction in treating neurodegeneration

For many families, it offers something that has been missing for a long time, which is cautious optimism.

Interested in Learning More?

If you are exploring TB006 or other advanced treatment options for Alzheimer’s or dementia, we’re happy to help guide you.

Reach out to Aevita Medical to schedule a consultation and discuss whether this approach may be appropriate for you or your loved one.

‍